How many patients has your trust treated in the past six months (for any disease) with the following drugs:
None of these drugs are even on our system - except the Zeposia, but it has never been used.
|
Drug Name
|
Patient Number
|
|
Aubagio (teriflunomide)
|
N/A
|
|
Avonex (interferon beta-1a)
|
N/A
|
|
Betaferon (interferon beta-1b)
|
N/A
|
|
Brabio (glatiramer acetate)
|
N/A
|
|
Copaxone (glatiramer acetate)
|
N/A
|
|
Extavia (beta interferon-1b)
|
N/A
|
|
Gilenya (fingolimod)
|
N/A
|
|
Kesimpta (ofatumumab)
|
N/A
|
|
Lemtrada (alemtuzumab)
|
N/A
|
|
Mavenclad (cladribine)
|
N/A
|
|
Mayzent (siponimod)
|
N/A
|
|
Ocrevus (ocrelizumab)
|
N/A
|
|
Plegridy (peginterferon beta-1a)
|
N/A
|
|
Ponvory (ponesimod)
|
N/A
|
|
Rebif (beta interferon-1a)
|
N/A
|
|
Tecfidera (dimethyl fumarate)
|
N/A
|
|
Tysabri (natalizumab)
|
N/A
|
|
Tysabri (natalizumab) Pre-filled syringes only
|
N/A
|
|
Vumerity (diroximel fumarate)
|
N/A
|
|
Zeposia (ozanimod)
|
NIL
|
Question Two
How many patients has you trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?
N/A
Question Three
How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?
|
|
Oct-23
|
Nov-23
|
Dec-23
|
Jan-24
|
Feb-24
|
Mar-24
|
|
Number of Admissions with a Primary or Secondary Diagnosis of Multiple sclerosis
|
34
|
37
|
29
|
37
|
41
|
19
|
Question Four
Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:
|
Condition
|
Patient Number
|
|
RRMS – Relapse Remitting Multiple Sclerosis
|
UNKNOWN
|
|
PPMS – Primary Progressive Multiple Sclerosis
|
UNKNOWN
|
|
SPMS – Secondary Progressive Multiple Sclerosis
|
UNKNOWN
|
The Trust is unable to provide this information as there is no specific codes for the above diagnoses and this information would require a manual search of all patients’ records which would take in excess of 18 hours as specified under Section 12 of the Freedom of Information Act.
